MHMichelle S. Hsiang

Michelle S. Hsiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michelle S. Hsiang has a total of 335 co-authors. Here are the top co-authors by number of shared publications:

  • Bryan Greenhouse

    Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, UCSF, San Francisco 94158, USA

    15 shared publications
  • Roly Gosling

    Department of Disease Control, London School of Hygiene and Tropical Medicine, London, UK

    15 shared publications
  • Davis Mumbengegwi

    Multidisciplinary Research Centre, University of Namibia, Windhoek 13301, Namibia

    9 shared publications
  • Nomcebo Dlamini

    National Malaria Elimination Programme, Ministry of Health, Manzini, Eswatini

    9 shared publications
  • Nyasatu Ntshalintshali

    Clinton Health Access Initiative, Eswatini Country Office, Mbabane, Eswatini

    9 shared publications
  • Adam Bennett

    Institute for Global Health Sciences, University of California, San Francisco (UCSF), San Francisco, USA

    8 shared publications

Latest Publications

  • Open Access

    Mass test and treat (MTaT) for malaria prevalence in a moderate transmission setting, a quasi-experimental trial from rural Ghana

    by Ndong Ignatius Cheng, Chuo Ennestine Chu, Xue Wu, Michael Ooko, Effah Baafi Yaw Jnr, Ndong Henry Ndang, Brandon Nji Amambua-Ngwa, Emily Amponsah, George Asumah Adu, Nana Yaw Peprah, et al.

    A principal challenge to reducing malaria transmission is the high prevalence of asymptomatic infections, whereby individuals without clinical symptoms continue to infect mosquitoes and sustain community-level transmission. Mass test and treat (MTaT), which involves screening populations and treating infected individuals, may reduce this hidden human reservoir, but evidence of its effectiveness in moderate transmission settings is limited. We conducted a two-year quasi-experimental study in 11 communities in the Pakro subdistrict of Ghana’s Eastern Region, an area with moderate malaria transmission. Seven communities received the MTaT intervention, while four served as controls. The intervention involved five rounds of MTaT delivered through community case management by trained community health volunteers. Community members were screened using rapid diagnostic tests, and those who tested positive were treated with artemether–lumefantrine. The primary outcome was malaria prevalence measured by rapid diagnostic tests, particularly among children aged 15 years or younger. An intention-to-treat analysis using mixed-effects Poisson regression models was applied. A total of 5,309 individuals participated, with 4,000 from intervention communities and 1,309 from control communities. MTaT coverage increased from 70.6% in March 2020 to 90.7% in March 2022. After adjusting for baseline malaria prevalence and insecticide-treated net use, overall malaria prevalence was 84% (aPR) of 0.16, 95% CI: 0.13–0.20, p < 0.001) lower in intervention communities than in controls. Among children aged 15 years or younger, prevalence was reduced by 89% (aPR = 0.11, 95% CI: 0.08–0.14; p < 0.001), while among individuals older than 15 years, prevalence was 74% (aPR = 0.26, 95% CI: 0.18–0.33; p < 0.001) lower in intervention communities. In conclusion, our findings suggest that implementation of MTaT over two years could contribute to reduction in malaria prevalence across all age groups in a moderate transmission setting. This approach could be considered as an effective strategy for reducing malaria burden and transmission in similar settings. Trial registration : NCT04301531, Date of Registration 03/04/2020. https://register.clinicaltrials.gov/prs/beta/records .

  • Open Access

    Socioeconomic disparities in children’s neurodevelopment before and during primary education: Evidence from Bagamoyo, Tanzania

    by Msilikale Walter Manyiri, Georg Loss, Susanne P. Martin-Herz, Deborah Sumari, Nicolaus Gutapaka, Thabit Athuman, Sylvester Simando, Sylvia Jebiwott, Xue Wu, Karim Manji, et al.

    Background: Socioeconomic disparities in children’s neurodevelopment constitute a critical yet understudied developmental challenge in low- and middle-income countries (LMICs), yet longitudinal evidence from Sub-Saharan Africa (SSA) remains limited. This study aimed to evaluate the relationship between household wealth and neurocognitive trajectories in a cohort of Tanzanian children aged 6 months to 10 years. Methods: We randomly selected 590 children aged 6 months to 10 years in Bagamoyo district, a low to moderate-malaria-endemic area in Tanzania. Participants completed comprehensive, age-appropriate neurodevelopmental assessments. The family’s socioeconomic status was derived from their household assets. Standardized, age-adjusted neurodevelopmental scores were regressed on socioeconomic status tertiles and by developmental periods: early childhood (6 months-3 years), preschool (4–5 years), and school age (6–10 years). Results: While children from high- and low-Socioeconomic status (SES) families start with similar neurodevelopmental scores, a significant and sustained gap begins to emerge around age 2 years. This divergence results in a substantial disadvantage for children from the poorest households, with scores showing a difference of −0.36 Standard Deviation (SD) (95% CI: −0.64 to −0.08) during the preschool years and −0.41 SD (95% CI: −0.73 to −0.09) at school age. Conclusion: Our results suggest that programs targeting the preschool period may be most effective in mitigating disparities in neurodevelopment.

  • Open Access

    Mapping the local effectiveness of mass drug administration for malaria using transportability methods

    by Michelle E. Roh, Yanwei Tong, Gabriella Barratt Heitmann, Junran Jia, El-Hadji Konko Ciré Ba, Jean Louis Ndiaye, Ari Fogelson, Paul Milligan, Amadou Seck, Abdoulaye Diallo, et al.

    Numerous trials have evaluated the effectiveness of mass drug administration (MDA) in rapidly reducing malaria transmission, but it is unknown whether the estimated effects generalize to other populations eligible for MDA. A recent cluster randomized trial in Senegal found that MDA reduced malaria incidence by 55% in areas that routinely deploy seasonal malaria chemoprevention (SMC). Here, we used transportability models with machine learning to generalize trial effects to 116 non-trial communes where SMC is the standard of care. Accounting for differences in weather, vegetation and population density between trial and non-trial areas, we estimated considerable reductions in incidence (ranging from 36% to 65%) in 74 non-trial communes, with larger decreases in areas having higher precipitation, denser vegetation and lower temperatures. We found that MDA was not effective in the postintervention year in non-trial communes, supporting the notion that MDA’s effects are short-lived. Our approach offers a scalable framework for generalizing trial findings to target environmentally mediated infectious disease interventions.


  • Open Access

    Using transportability methods to map the local effectiveness of mass drug administration for malaria in Senegal

    by Michelle E. Roh, Yanwei Tong, Gabriella R Barratt Heitmann, El-Hadji Konko Ciré Ba, Jean Louis Ndiaye, Ari Fogelson, Paul Jm Milligan, Amadou Seck, Abdoulaye Diallo, Aminata Colle Lo, et al.

    Numerous trials have evaluated the effectiveness of mass drug administration (MDA) to rapidly reduce malaria transmission, but it is unknown whether estimated effects generalize to other populations eligible for MDA. A recent cluster-randomized trial in Senegal found that MDA reduced malaria incidence by 55% in areas routinely deploying seasonal malaria chemoprevention (SMC). Here, we used transportability models with machine learning to generalize trial effects to 116 non-trial Communes where SMC is standard-of-care. Accounting for differences in weather, vegetation, and population density between trial and non-trial areas, we estimated significant reductions in incidence of 36%–65% in 74 non-trial Communes, with larger reductions in areas with higher precipitation, denser vegetation, and lower temperatures. We found that MDA was not effective in the post-intervention year in non-trial Communes, supporting the notion that MDA effects are short-lived. Our approach offers a scalable framework for generalizing trial findings to target environmentally-mediated infectious disease interventions.

  • Open Access

    Exploring Heterogeneity in Treatment Effects: The Impact and Interaction of Asset-Based Wealth and Mass Azithromycin Distribution on Child Mortality

    by Elisabeth A. Gebreegziabher, Ali Sie, Mamadou Ouattara, Mamadou Bountogo, Boubacar Coulibaly, Valentin Boudo, Thierry Ouedraogo, Elodie Lebas, Huiyu Hu, Pearl Anne Ante-Testard, et al.

    Objective To examine how child mortality among children aged 1–59 months varies by asset-based wealth status in rural Burkina Faso and to assess the interaction between mass azithromycin distribution and wealth status on child mortality at both the household and community levels. Methods We used data from a cluster-randomized trial and a population census data on household characteristics and assets. A wealth index score for each household, used to classify the population by wealth was generated using principal component analysis. We used the Relative Index of Inequality (RII), the Slope Index of Inequality (SII), and the concentration index to assess wealth-related inequalities in mortality, and the Gini Index to assess variability in child mortality across households and communities. Poisson regression models were used with person-time at risk included as an offset and robust standard error to estimate changes in mortality rates by wealth and treatment arm. We assessed interaction on both the multiplicative and additive scales. Results Mortality declined with increasing wealth at both household and community levels, with a significant gradient at the community level (RII = 1.17, 95% CI: 1.05–1.29; SII = 2.3 per 1,000 person-years, 95% CI: 0.2–4.4), reflecting higher mortality among the poorest. The effect of AZ did not vary significantly by wealth index, and the change in mortality rates across wealth levels was similar between the two treatment arms. There was no statistically significant interaction between AZ and asset-based wealth on either a multiplicative or additive scale at the household or cluster level. Conclusion Our findings show a wealth gradient in child mortality, with households and communities in the poorest quintiles experiencing the highest mortality rates. These disparities were consistent across both AZ-treated and placebo groups, suggesting that AZ’s role in health disparities may primarily address gaps in treatment access rather than broader wealth-related disparities. AZ appears to offer similar benefits across economically diverse communities, with no evidence suggesting enhanced benefits for disadvantaged communities or for prioritizing treatment based on wealth status. Further work is needed to address the wealth-related disparities in child mortality in these communities. Trial Registration ClinicalTrials.gov Identifier: NCT03676764

  • Open Access

    Indirect Benefits of Seasonal Malaria Chemoprevention for Non-Malarial Pediatric Infections and Routine Antibiotic Use in Real-World Programmatic Settings: A Pre-Post Study Using Positive and Negative Controls

    by Elisabeth A. Gebreegziabher, Mamadou Ouattara, Mamadou Bountogo, Boubacar Coulibaly, Valentin Boudo, Thierry Ouedraogo, Elodie Lebas, Huiyu Hu, Kieran S. O’brien, Michelle S. Hsiang, et al.

    Objective To assess the benefits of Seasonal Malaria Chemoprevention (SMC), the monthly administration of sulfadoxine-pyrimethamine and amodiaquine during the high malaria season, beyond malaria prevention in real-world program settings. Methods We conducted a pre-post comparison of non-malarial diagnoses (pneumonia, diarrhea, acute malnutrition) and antibiotic prescription rates during SMC administration weeks versus a three-week post-intervention period in rural Burkina Faso. Data came from clinic surveillance at 51 health facilities, a population-based census, and National Malaria Control Program data on SMC timing. Poisson regression models with person-weeks as an offset and standard errors clustered by health post estimated changes in rates. Interaction terms assessed variation across SMC cycles. Positive (malaria diagnoses, antimalarial prescriptions) and negative (injury) control outcomes were used to evaluate potential unmeasured confounding. Results Compared to administration weeks, modest declines were observed in pneumonia, diarrhea, and acute malnutrition diagnoses, as well as in antibiotic prescription rates during the post-SMC period. Absolute reductions were 0.7 (95% CI: 0.3–1.0), 0.2 (95% CI: 0.1–0.4), 0.05 (95% CI: 0.001–0.09), and 0.90 (95% CI: 0.4–1.4) per 1,000 person-weeks, respectively. Positive control outcomes also declined, with malaria diagnoses and antimalarial prescriptions decreasing by 3.7 (95% CI: 2.6–4.8) and 3.6 (95% CI: 2.5–4.7) per 1,000 person-weeks. Injury rates (negative control) remained stable (0.02; 95% CI: −0.03 to 0.07). Reductions varied across SMC cycles and were most pronounced following the final round. Conclusion SMC may have additional benefits beyond malaria prevention, including reductions in common pediatric infections and subsequent routine antibiotic use.

  • Open Access

    Characterisation of between-cluster heterogeneity in malaria cluster randomised trials to inform future sample size calculations

    by Joseph Biggs, Joseph Challenger, Dominic Dee, Eldo Elobolobo, Carlos Chaccour, Francisco Saute, Sarah Staedke, Sibonakaliso Vilakati, Jade Benjamin-Chung, Michelle Hsiang, et al.

    Cluster randomised trials (CRTs) are important tools for evaluating the community-wide effect of malaria interventions. During the design stage, CRT sample sizes need to be inflated to account for the cluster-heterogeneity in measured outcomes. One such measure of heterogeneity, the coefficient of variation (k), is typically used in malaria CRTs yet is often estimated without prior data. Underestimation of k undermines study power and increases the probability of CRTs generating null results. We conducted a meta-analysis of cluster-summary data from 24 malaria CRTs and calculated true k values for prevalence and incidence outcomes using methods-of-moments and regression modelling approaches. Using random effects regression modelling we investigated the impact of empirical k values on original trial power, effect size uncertainty and explored associated factors. Results revealed empirical estimates of k often exceeded those used in sample size calculations which heavily contributed to compromised study power and effect size precision. Increased between-cluster heterogeneity of outcomes was associated with outcome measures (i.e. incidence or prevalence), lower endemicity, seasonality of surveys and uneven intervention coverage across clusters. Study findings can be used to inform future malaria CRT sample size calculations and trial design to help ensure malaria interventions are effectively and feasibly evaluated.

  • Open Access

    Estimating malaria antigen dynamics and the time to negativity of next-generation malaria rapid diagnostic tests

    by William Sheahan, Allison Golden, Rebecca Barney, Smita Das, Ihn-Kyung Jang, Henry Ntuku, Xue Wu, Brooke Whittemore, Lucille Dausab, Davis Mumbengegwi, et al.

    Background: Rapid diagnostic tests (RDTs) used to diagnose Plasmodium falciparum (Pf) predominantly target the antigen Histidine Rich Protein 2 (HRP2) exclusively. With the emergence of hrp2/hrp3 gene deletions, RDTs targeting other antigens such as the essential enzyme Lactate Dehydrogenase (LDH) are needed. The dynamics of LDH relative to HRP2 are currently not well described but are needed to inform the use of next-generation (NG-) LDH and HRP2 RDTs that are designed to address hrp2/hrp3 gene deletions. Methods: A longitudinal cohort study conducted in a low transmission setting in Namibia was leveraged to compare HRP2 and LDH decay rates. Passive and active case detection were used to recruit individuals with positive HRP2-RDT results. Study participants were treated and subsequently followed weekly until they received two consecutive HRP2-RDT negative results. Blood specimens were characterized for antigen concentration and parasite density. Antigen decay rates were calculated and used to estimate time to negativity (TTN) of NG-RDTs: two HRP2 and LDH-based RDTs (Rapigen Pf and a WHO prequalified Pf/Pv RDT) and an LDH-only RDT (Rapigen Pf/Pv). Results: In 135 participants, the starting geometric mean concentrations for HRP2 and LDH were 899 ng/mL and 344 ng/mL respectively. Both antigens followed a biphasic decay rate, with a faster decay rate in the first phase. For current RDTs with an analytical sensitivity of 1 ng/mL for HRP2 and 5 ng/mL for LDH, TTN was 44 and 4 days, respectively. With a NG-RDT with LDH analytical sensitivity of 0.37 ng/mL, average TTN was 9 days. Multiple levels of analytical sensitivity were also modeled. Conclusions: In the detection of Pf malaria, LDH versus HRP2-based RDTs had a faster TTN due to a combination of lower accumulated antigen concentrations and faster decay rates, even for more sensitive LDH-based RDTs. Detection of LDH versus HRP2 by RDT is more likely to reflect a new or very recent infection. For NG-RDTs that target both antigens, HRP2 is likely to contribute more to the test signal than LDH in recently treated infections unless the infection has hrp2/hrp3 gene deletions. Antigen decay data combined with analytical sensitivity of RDTs contributes to our understanding of their performance and interpretation.


  • Open Access

    Usability and psychometric properties of a battery of tools to assess intelligence, executive functioning, and sustained attention in Tanzanian children

    by Georg Loss, Hannah Cummins, Nicolaus Gutapaka, Jane Nyandele, Sylvia Jebiwott, Deborah Sumari, Thabit Athuman, Omary Juma, Susanne P. Martin-Herz, Ally Olotu, et al.

    Background: Measuring neurocognitive functioning in children requires validated, age-appropriate instruments that are adapted to the local cultural and linguistic context. We sought to evaluate the usability and psychometric properties of five tools that assess general intelligence, executive functioning, and sustained attention among Tanzanian children. Methods: We adapted five age-appropriate neurocognitive assessment batteries from previously published assessment materials to the Tanzanian context. We enrolled children 6 months to 12 years of age residing in the rural ward of Yombo, Pwani Region. Feasibility and acceptability of all instruments was assessed qualitatively and quantitatively, including measurement of refusal rates, ceiling or floor effects, and time requirements. We assessed internal consistency using Cronbach’s alpha and convergent validity using standard correlation analysis. Score gradients across age were explored using polynomial regression analysis. Findings: All five instruments required minimal adaptations to the Tanzanian context. Two-hundred sixty one children aged 6 months to 12 years completed the assessment. Refusal rates were consistently low (5.9% at the highest) and no ceiling or floor effects of measurements were observed. Feedback from assessors and caregivers indicated adequate test durations and generally high acceptability of instruments. All instruments showed good internal consistency with Cronbach alphas at least 0.84 for all tests. We found satisfactory convergent validity; all test scores strongly correlated with age. Conclusion: The five instruments identified to assess general intelligence, executive functioning, and sustained attention constructs in Tanzanian children seem to work well in this setting.


  • Open Access

    Trends in malaria prevalence over 15 years (2006–2021) in Jakiri North-West Region, Cameroon

    by Ndong Henry Ndang, Njodzela Christian Mengnjo, Palmer Masumbe Netongo, Ngala Hanson Chuye, Chuo Ennestine Chu, Michelle Hsiang, Juliana Yartey Enos, Alfred Amambua-Ngwa, Ndong Ignatius Cheng